UNSPSC 51284140: Cefsulodin sodium

This classification denotes the sodium form of an anti-bacterial agent with the molecular formula C22H20N4O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OV42LHE42B, chemically known as 4-carbamoyl-1-(((6r,7r)-2-carboxy-8-oxo-7-((2r)-2-phenyl-2-sulfoacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)pyridinium hydroxide, inner salt, monosodium salt but more generally known as cefsulodin, which bears US NIH Compound Identifier 40246.

UNSPSC 51284140 Cefsulodin sodium is a Commodity code for pharmaceutical supply procurement, though recent state and local opportunities tagged under this code do not reflect cefsulodin specifically. Instead, state and local governments are using this code category to solicit broader pharmaceutical products including antibiotics, opioid antagonists, and drug deactivation systems through warehouse supply and direct purchase arrangements. The scope of work spans bulk pharmaceutical inventory replenishment for health departments and county health systems, delivered through piggyback contracts on established pharmaceutical consortiums or through competitive bidding for recurring annual supply needs. Issuing bodies include state health departments and county governments; the Illinois Department of Public Health and Seminole County, Florida appear in recent postings.

Recent opportunities show activity in Illinois and Florida. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for antibiotic tablets (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg) totaling $2,999,999.11 over 12 months with two renewal options, selected via Invitation for Bid. Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford; the response deadline was July 26, 2023, with a two-year initial term and one-year renewal option. Vendors in both cases must cover all shipping and delivery costs, maintain required insurance, and comply with drug-free workplace and E-Verify requirements.